NCT02507336 2024-08-01
Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
University of Miami
Phase 2 Completed
Clinical Trials
13 trialsNCT01125176 2022-01-21
ThRiL
Weill Medical College of Cornell University
Phase 2 Completed
NCT02733380 2020-04-01
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Unknown
NCT03335098 2017-11-07
BOMB-THROW
Seoul National University Hospital
Phase 2 Unknown
NCT00723658 2015-03-06
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00357500 2014-10-01
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00142116 2014-06-02
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00958854 2013-08-26
Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00009984 2013-06-06
Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00015912 2013-01-25
Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00083707 2010-07-05
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
University of Arkansas
Phase 2 Completed
NCT00373646 2009-06-18
Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
Medical University of Vienna
Phase 2 Completed
NCT00209014 2009-05-07
Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease
Emory University
Phase 2 Terminated